DFTX stock news
This page provides real-time market news, earnings updates, and company announcements related to Definium Therapeutics, Inc. (DFTX).
All content is aggregated from trusted financial media and market data sources to help investors stay informed about key market movements and corporate developments.
Last updated as of 2026-07-06 02:05 EST
Jefferies Assigns 65-75% Probability of Best-in-Class Efficacy for Definium Therapeutics, Inc.'s (DFTX) DT120 in Phase III
Finviz2026-02-19 02:33:45
Magic Mushrooms, Hard Cash: Compass Pathways' Trial Win, Fast Raise
Finviz2026-02-20 16:15:09
Investment bank Piper Sandler announced the official initiation of coverage on biopharmaceutical company Definium Therapeutics Inc, assigning it an "Overweight" rating.
老虎证券2026-04-10 03:37:12
The Nasdaq Biotechnology Index closed up more than 1.52%. Among its constituents, Absci surged 35.96%, Silence Therapeutics rose 26.00%, and Aardvark Therapeutics, Definium Therapeutics, Black Diamond, Personalis, and Adaptive Biotechnologies gained between 17.73% and 12.25%.
华尔街见闻2026-06-24 21:40:03
DFTX stock chart
DFTX stock detailsDFTX stock price change
On the last trading day, DFTX stock closed at 44.19 USD, with a price change of 1.82% for the day.
Trade spot stocks (24/7)Trade stock perps (up to 100x leverage)About Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
To provide deeper liquidity, a more transparent trading experience, and greater capital efficiency, Bitget officially launched its all-new spot stock product, Bitget Stocks 2.0, on June 2, 2026.
The new product is independently issued by licensed RWA protocol Reality, with Bitget providing strategic support and asset security safeguards. This marks a major upgrade to the stock trading experience.
Bitget is moving stock trading beyond the limits of traditional trading models by fully integrating stock assets into its margin and yield ecosystem.
Learn more